BioSpace News Archive

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported third quarter 2020 financial results and provided a corporate update.

Company expects to initiate pivotal trial of AVB-500 in Platinum Resistant Ovarian Cancer during fourth quarter 2020/first quarter 2021, based on Phase 1b results

Aerpio Pharmaceuticals, Inc. will release its financial results for the third quarter ended September 30, 2020, before the market open on Tuesday, November 10, 2020, and host a webcast and conference call at 8:30am ET.

Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21

NUZYRA® (omadacycline) Generated Net Product Revenue of $10.9 Million in the Third Quarter 2020; a 35% Increase Over the Prior Quarter

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it plans to release its third quarter earnings results after market close on Thursday, November 19, 2020.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced its financial results for the three months ended September 30, 2020 and provided a corporate update.

Pfizer Inc. (NYSE: PFE) announced today further details regarding the proposed spin-off of its Upjohn Business and the subsequent combination of Mylan and the Upjohn Business to form Viatris Inc. As previously announced, Pfizer has set the close of business on November 13, 2020 as the record date for the spin-off, and the combination of Mylan and the Upjohn Business is expected to close on November 16, 2020. No action is re

John Wiley and Sons (NYSE: JW-A and JW-B), a global leader in research and education, announced today that management will participate in the Citi investor conference – Fast Forward to the Future: Accelerating Edtech Adoption in a Post-COVID-19 World – on Thursday, November 12. Brian Napack, President and Chief Executive Officer, and John Kritzmacher, Chief Financial Officer, will participate in a virtual firesid

Eurofins CDMO announces the strategic expansion of its existing Drug Product operation capabilities with the early 2020 completion of its new Drug Product development and cGMP manufacturing facility, located in Mississauga, Canada.